Skip to search formSkip to main contentSkip to account menu

Antiparkinson Agents

Known as: antiparkinsonian drugs, ANTI-PARKINSON DRUGS, Antiparkinson Drugs 
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or… 
National Institutes of Health

Related topics

Related topics

47 relations

Narrower (38)

24 HR Pramipexole dihydrochloride 0.75 MG Extended Release Oral Tablet24 HR Rotigotine 0.0417 MG/HR Transdermal System24 HR Rotigotine 0.25 MG/HR Transdermal SystemApomorphine

Broader (1)

Central Nervous System Depressants
Cholinergic AntagonistsDopamine AgonistsIn BloodParasympatholytics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic… 
Highly Cited
2010
Highly Cited
2010
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
BACKGROUND Deep-brain stimulation is the surgical procedure of choice for patients with advanced Parkinson's disease. The globus… 
Highly Cited
2009
Highly Cited
2009
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Highly Cited
2005
Highly Cited
2005
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.
The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration of… 
Highly Cited
2002
Highly Cited
2002
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor…
Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents… 
Highly Cited
2000
Highly Cited
2000
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They… 
Review
1996
Review
1996
Neuropharmacology of timing and time perception.
  • W. Meck
  • Brain research. Cognitive brain research
  • 1996
  • Corpus ID: 7031554
Review
1993
Review
1993
Dopamine receptor pharmacology.
Highly Cited
1989
Highly Cited
1989
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's… 
Review
1961
Review
1961
A survey of drug-induced extrapyramidal reactions.
  • F. Ayd
  • JAMA
  • 1961
  • Corpus ID: 8768642
Among 3,775 patients treated with tranquilizers of the phenothiazine group, 1,472 developed extrapyramidal reactions; 21.2% had… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)